Homologous News and Research

RSS

Research using kidney organoids may lead to new targets to help prevent or treat CKD

To a certain extent, kidneys have the capacity to repair themselves after being injured, but a switch can occur from such intrinsic repair to incomplete repair that leads to irreversible damage and chronic kidney disease (CKD).

12 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

In a new study, researchers characterized over 100 SARS-CoV-2-specific CD4+ T-cell epitopes.

8 Apr 2022

Molecular signature of highly stereotyped clonotypic anti-PF4 antibodies indicates shared pathways of antibody production in VITT patients

A recent study analyzed the antibody that mediated the COVID-19 vaccine-induced thrombotic thrombocytopenia.

7 Apr 2022

Study demonstrates cross-neutralization among SARS-CoV-2 Omicron sublineages

Researchers assessed the cross-neutralization among three sublineages of the SARS-CoV-2 Omicron variant: BA.1, BA.2, and BA.3 sublineages, and an additional strain, USA/WA1-2020 (wild-type) in mice.

5 Apr 2022

“MixOmicron” SARS-CoV-2 recombinant evades variant screening

A new study describes a new variant that resembles the SARS-CoV-2 Omicron BA.21 for the most part but has a small segment at the 3’ tip that belongs to the BA.1 variant.

5 Apr 2022

The SAVE initiative to monitor the impact of SARS-CoV-2 variants

The SAVE initiative assesses the impact of SARS-CoV-2 variants on diagnostics, vaccines, and therapies, as well as communicating public health dangers.

4 Apr 2022

Magnitude and durability of SARS-CoV-2 S-binding antibody titers in the pre-variant era among healthcare workers in NYC

Researchers analyzed sera samples of 400 participants of the PARIS study to evaluate the risk of SARS-CoV-2 infection and seroreversion for an average of 84 days.

4 Apr 2022

Researchers explore a novel method to isolate monoclonal antibodies from COVID-19 convalescents infected with SARS-CoV-2 variants

Researchers developed a novel high-throughput method to obtain monoclonal antibodies from COVID-19 individuals infected with SARS-CoV-2 ancestral strain Wuhan-Hu-1 and the Beta or Gamma variants.

1 Apr 2022

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Researchers bioengineered a divalent fusion vaccine by combining the immunogenic region of the nucleocapsid protein and the receptor-binding domain of the spike protein of SARS-CoV-2.

30 Mar 2022

Immune response dynamics following COVID-19 heterologous and homologous vaccinations

Researchers evaluated the cellular and humoral immunity following heterologous and homologous COVID-19 immunization regimens for up to five months.

29 Mar 2022

Newcastle disease virus-based trivalent vaccine found to be effective across SARS-CoV-2 variants in mice

In a new study, researchers tested the bi-, tri-, and tetravalent formulations of Newcastle disease virus (NDV)-based low-cost vaccine in mice.

29 Mar 2022

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

A new study presented the differences among total anti-SARS-CoV-2 antibodies following SARS-CoV-2 Pfizer primary and booster vaccinations.

24 Mar 2022

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Researchers evaluated the effectiveness of a novel vaccine candidate UB-612 against 14 SARS-CoV-2 variants, including the latest variant of concern, Omicron.

24 Mar 2022

Waning antibody responses in SARS-CoV-2-infected or vaccinated population

A recent study posted to the bioRxiv* preprint server evaluated the effects of the waning of antibodies after coronavirus disease 2019 (COVID-19) infection or vaccination.

22 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

HRR mutational status associated with survival outcomes in recurrent platinum-sensitive ovarian cancer

Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented at a Seminal Session during the Society for Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer in March 2022.

19 Mar 2022

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

Scientists evaluate the humoral and cellular immune responses in individuals who have received a third booster dose of mRNA-based COVID-19 vaccine.

17 Mar 2022